FY2027 EPS Estimates for VRTX Lowered by Erste Group Bank

Posted by Geri Gentry on Jun 11th, 2026

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) – Analysts at Erste Group Bank decreased their FY2027 earnings estimates for shares of Vertex Pharmaceuticals in a report issued on Friday, June 5th. Erste Group Bank analyst H. Engel now expects that the pharmaceutical company will earn $19.24 per share for the year, down from their previous estimate of $19.36. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $17.02 per share.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The business had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $2.99 billion. During the same quarter in the prior year, the business posted $4.06 EPS. The company’s revenue for the quarter was up 8.3% on a year-over-year basis.

VRTX has been the subject of several other research reports. Maxim Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $575.00 target price for the company in a report on Wednesday, March 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $590.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, May 18th. Royal Bank Of Canada increased their price target on shares of Vertex Pharmaceuticals from $541.00 to $543.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Finally, Barclays increased their price target on shares of Vertex Pharmaceuticals from $607.00 to $615.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Twenty-two analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $555.91.

Read Our Latest Analysis on Vertex Pharmaceuticals

Vertex Pharmaceuticals Trading Down 2.3%

Shares of Vertex Pharmaceuticals stock opened at $435.71 on Thursday. The company has a fifty day simple moving average of $437.22 and a 200-day simple moving average of $452.25. Vertex Pharmaceuticals has a 12-month low of $362.50 and a 12-month high of $507.92. The stock has a market cap of $110.58 billion, a price-to-earnings ratio of 25.84, a PEG ratio of 1.91 and a beta of 0.30.

Insider Buying and Selling

In related news, EVP Joy Liu sold 1,104 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $425.02, for a total transaction of $469,222.08. Following the completion of the sale, the executive vice president owned 20,729 shares in the company, valued at $8,810,239.58. This represents a 5.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 318 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $423.73, for a total transaction of $134,746.14. Following the sale, the director owned 4,924 shares of the company’s stock, valued at approximately $2,086,446.52. This represents a 6.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,462 shares of company stock worth $6,095,195 in the last 90 days. Company insiders own 0.20% of the company’s stock.

Institutional Trading of Vertex Pharmaceuticals

Several hedge funds have recently made changes to their positions in VRTX. Danske Bank A S purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $64,417,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Vertex Pharmaceuticals by 3.8% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 544,978 shares of the pharmaceutical company’s stock valued at $213,435,000 after purchasing an additional 20,053 shares in the last quarter. Leuthold Group LLC purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $5,030,000. Legacy Capital Group California Inc. purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $956,000. Finally, ING Groep NV purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $4,695,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

(Get Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.